After an illustrious career as chief scientific officer at Johnson & Johnson, Dr Paul Stoffels is ready for a new chapter in his home country, with Belgian biot 2 February 2023
The world’s leading biopharma companies experienced growth in market capitalization of 5.4% on average last year, according to industry analyst GlobalData. 30 January 2023
More gloomy news from Finch Therapeutics, as the microbiome company announced it would scrap the Phase III PRISM4 trial of its recurrent C. difficile infection 25 January 2023
French pharma major Sanofi has announced an additional multi-year commitment into its evergreen venture fund, with an increase in capital to more than $750 mill 12 January 2023
Boston-based Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, has announ 9 January 2023
One of the world’s leading specialists in mRNA therapeutics has partnered with California’s CytomX Therapeutics to create novel cancer meds. 6 January 2023
Cratering shares in Cambridge, Massachusetts-based inflammatory disease company Third Harmonic Bio reflect a loss in confidence after a Phase I failure. 16 December 2022
A Danish company developing a vaccine against group B streptococcus (GBS)—an infection often known as Strep B—has 72 million ($77 million) euros more to spend. 15 December 2022
French drug resistance specialist Ribonexus has appointed Steven Powell as chief executive, as the company prepares to seek more financing for its small molecul 14 December 2022
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news